Prescription Medicines
Starzin Tab. 50mg
- Product Category
- diabetes medication
- Active Ingredients
- Sitagliptin Phosphate
- Appearance
- Light beige, round, biconvex film-coated tablets
- Reimbursement Code
- 648103620
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredient: Sitagliptin phosphate (in-house specification) · · · · · · · 62.04mg (50mg as sitagliptin)
- Additives: Anhydrous calcium hydrogen phosphate, microcrystalline cellulose, magnesium stearate, Opadry II light beige (85F17498), croscarmellose sodium, sodium stearyl fumarate
2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve blood sugar control in patients with type 2 diabetes.
1. This drug is administered as monotherapy.
2. If there is no previous experience of diabetes medication and it is difficult to control blood sugar levels sufficiently with monotherapy, administer in combination with metformin.
3. If sufficient blood sugar control cannot be achieved with sulfonylurea, metformin, thiazolidinedione, or insulin alone, administer this drug together.
4. If sufficient blood sugar control cannot be achieved with combination therapy of sulfonylurea and metformin, or combination therapy of thiazolidinedione and metformin, or combination therapy of insulin and metformin, this drug should be administered together.
3. Dosage and dosage
This drug is administered at a dose of 100 mg once a day when used as monotherapy or combination therapy, and the maximum daily dose is 100 mg. This medicine can be taken without regard to meals.
When coadministered with sulfonylurea or insulin, reduction of sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea or insulin-induced hypoglycemia.
(Refer to Precautions for Use, Section 5. General Precautions).
Patients with renal impairment
Since dose adjustment is necessary depending on renal function, it is recommended to evaluate renal function periodically before and after administration of this drug.
1. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2).
2. No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2).
3. In patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once a day.
4. Patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis.
(Glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once a day. This drug can be administered regardless of the timing of dialysis.
4. Precautions for use
1. Warning
1) Hypersensitivity reaction
Severe hypersensitivity reactions have been reported in patients receiving this drug post-marketing, including anaphylaxis, angioedema, and exfoliative skin disorders, including Stevens-Johnson syndrome. Because they are voluntarily reported from an unspecified population, it is generally not possible to reliably estimate their incidence or establish a causal relationship with drug exposure. The onset of this reaction occurred within the first 3 months of drug treatment and has also been reported after the first dose. If hypersensitivity reaction is suspected, discontinue this drug, evaluate other potential reasons for the occurrence, and implement other diabetes treatment (see 2. Do not administer to the following patients and 4. Adverse reactions, 2) Post-marketing adverse reactions).
2) Pancreatitis
Acute pancreatitis, including fatal/non-fatal hemorrhagic or necrotizing pancreatitis, has been reported in patients receiving sitagliptin (see Section 4. Adverse Reactions). After starting treatment with this drug, carefully observe whether symptoms of pancreatitis appear. If pancreatitis is suspected, administration of this drug and other suspected drugs should be discontinued.
2. Do not administer to the following patients
1) Patients with type 1 diabetes or diabetic ketoacidosis
2) Patients with known hypersensitivity such as anaphylaxis or angioedema to this drug or its components (see 1. Warning section)
3. Administer with caution to the following patients:
1) Patients with renal impairment: This drug is excreted through the kidneys. To achieve blood levels similar to those in patients with normal renal function, lower doses are recommended in patients with a glomerular filtration rate [eGFR] <45 mL/min/1.73 m2? and in patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (see Dosage and Administration, Patients with Renal Impairment).
4. Adverse reactions
1) Clinical trials
Because clinical trials are conducted under a wide range of diverse conditions, the incidence of adverse reactions observed in clinical trials cannot be directly compared to the rates in clinical trials of other drugs, and cannot reflect the rates observed under actual use environments.
In clinical trials of this drug, when this drug was administered as monotherapy or combination therapy (metformin or pioglitazone or rosiglitazone and metformin), the incidence of adverse reactions and hypoglycemia was generally similar to that reported for placebo. Cases where treatment was discontinued due to adverse reactions were similar to those in the placebo group.
During glimepiride or glimepiride and metformin combination therapy, the frequency of adverse reactions in the drug-treated group was higher than the placebo group (Table 3). This is partly due to the high incidence of hypoglycemia in the group receiving this drug. Discontinuation of treatment due to adverse reactions was similar to that in the placebo group.
Two placebo-controlled monotherapy studies conducted for 18 and 24 weeks included groups receiving 100 mg and 200 mg of this drug daily and placebo. Five additional placebo-controlled combination studies administered metformin, pioglitazone, rosiglitazone, and stable doses of metformin, glimepiride (±metformin), or insulin (±metformin), respectively, plus 100 mg of this drug or placebo daily.
In these clinical trials, adverse reactions reported at a frequency of 5% or more and more frequently than placebo among patients taking 100 mg of this drug daily for 18 weeks, regardless of causality assessment, excluding hypoglycemia, are listed in Table 1. The incidence of hypoglycemia is shown in Table 3.
Table 1. Placebo-controlled clinical trials with this drug as monotherapy or in combination (pioglitazone, or rosiglitazone and metformin, or glimepiride (±metformin)): Adverse reactions, excluding hypoglycemia, reported at a frequency of 5% or more and more frequently than placebo, regardless of causality assessment†
* Table: refer to manual
† ITT (Intent-to-treat) subject group
In patients who received additional co-administration of this drug and metformin for 24 weeks, there were no adverse reactions reported at a frequency of more than 5% and more frequently than placebo, regardless of causality assessment.
In patients who received this drug in combination with a stable dose of insulin (±metformin) for 24 weeks, there were no adverse reactions except hypoglycemia, which was reported at a frequency of more than 5% and more frequently than placebo, regardless of causality assessment (see Table 3 for hypoglycemia). In patients receiving additional co-administration of this drug during another 24-week insulin intensification period (±metformin), the adverse reaction reported at a frequency greater than 5% and more frequently than placebo, regardless of causality assessment, was diarrhea (5.2% of this drug; 3.3% of placebo).
In patients receiving this drug in combination with rosiglitazone and metformin for 54 weeks, adverse reactions reported at a frequency of 5% or more and more frequently than placebo, regardless of causality assessment, were: upper respiratory tract infection (15.5% of this drug, 6.2% of placebo), nasopharyngitis (11.0%, 9.3%), peripheral edema (8.3%, 5.2%), and headache (5.5%). It was 4.1%).
As a result of a comprehensive analysis of two monotherapy clinical trials, a clinical trial with additional combination therapy with metformin, and a clinical trial with additional combination therapy with pioglitazone, the occurrence of specific gastrointestinal adverse reactions in patients treated with this drug was as follows: abdominal pain (2.3% with this drug 100 mg, 2.1% with placebo), nausea (1.4% with this drug 100 mg, 0.6% with placebo), and diarrhea (100 mg with this drug). 3.0%, placebo 2.3%)
In a 24-week placebo-controlled factorial trial, adverse reactions that were reported at a frequency of 5% or more or more frequently than placebo, regardless of the causality assessment, during initial co-administration of this drug and metformin are listed in Table 2.
Table 2. Initial combination therapy with this drug and metformin: Adverse reactions reported at a frequency of 5% or more and more frequently than those administered with this drug alone, metformin alone, and placebo, regardless of causality assessment†
* Table: refer to manual
† ITT (Intent to treat) subject group
‡ Integrated data of patients receiving low and high doses of metformin
No clinically significant changes in vital signs or ECG (including QTc interval) were observed with administration of this drug.
pancreatitis
When the results of 19 double-blind clinical trials of 10,246 patients randomly assigned to sitagliptin 100 mg/day (N=5429) or the corresponding control group (active comparator or placebo) (N=4817) were pooled and analyzed, the incidence of acute pancreatitis in each group was 0.1 per 100 patient-years (in the sitagliptin group) reported in 4 patients out of 4708 patient-years and in the control group in 4 patients out of 3942 patient-years). In the TECOS cardiovascular safety trial, the incidence of acute pancreatitis was reported to be 0.11 (23/7,332, 25 cases) per 100 patient-years in the sitagliptin group and 0.06 (12/7,339, 17 cases) per 100 patient-years in the placebo group. (See 1. Warning, 2) Pancreatitis section, TECOS cardiovascular safety clinical trial section)
TECOS Cardiovascular Safety Trial (TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin)
The intent-to-treat arm of the cardiovascular safety clinical trial of this drug included 7,332 patients who received 100 mg of this drug daily (or 50 mg daily if eGFR ≥ 30 and <50 mL/min/1.73 m2 at baseline) and 7,339 patients who received placebo. In this clinical trial, this drug or placebo was administered in addition to usual treatment in each country related to glycated hemoglobin (HbA1c) and cardiovascular (CV) risk factors. Administration of this drug did not increase the risk of hospitalization due to major cardiovascular disease or heart failure (see Section 9. Other). The reported incidence of serious adverse reactions was similar at 12.7% in the drug-treated group and 12.4% in the placebo-treated group.
Severe hypoglycemia was reported in 2.2% of the this medicine group (160 patients; 0.78 per 100 patient-years) and 1.9% of the placebo group (143 patients; 0.70 per 100 patient-years). Among patients receiving insulin and/or a sulfonylurea, the incidence was 2.7% with this medicine (138/5,021 patients) and 2.5% with placebo (125/4,931 patients). Among patients not receiving insulin or a sulfonylurea, the incidence was 1.0% with this medicine (22/2,311 patients) and 0.7% with placebo (18/2,408 patients). Confirmed acute pancreatitis occurred in 0.3% of the this medicine group and 0.2% of the placebo group.
low blood sugar
In all studies (9), hypoglycemic adverse events were based on reports of symptomatic hypoglycemia. Although blood sugar measurement was not necessarily involved, most reports of hypoglycemia (74%) were below 70 mg/dL when measured. The proportion of patients with one or more hypoglycemic adverse events when this drug was administered in combination with a sulfonylurea or insulin was higher than in the placebo group (see Table 3).
Table 3. Placebo-controlled clinical trials administering this drug in combination with glimepiride (±metformin) or insulin (±metformin): Incidence of reported hypoglycemia, regardless of causality assessment†
* Table: refer to manual
† Hypoglycemic adverse events were based on reports of symptomatic hypoglycemia and were not necessarily accompanied by blood glucose measurements; ITT (Intent to treat) group
‡ Based on total number of incidents (a person may report multiple incidents)
§ Severe hypoglycemia was defined as requiring medical attention, reaching a reduced level of consciousness, losing consciousness, or having a seizure.
As a result of a comprehensive analysis of two monotherapy clinical trials, a clinical trial with additional combination therapy with metformin, and a clinical trial with additional combination therapy with pioglitazone, the incidence of hypoglycemia as an adverse reaction in patients administered 100 mg of this drug was similar to that of placebo (1.2% for 100 mg of this drug, 0.9% for placebo).
In a clinical trial combining this drug with rosiglitazone and metformin, the incidence of hypoglycemia up to 18 weeks was 2.2% in the drug-treated group and 0.0% in the placebo-treated group. The incidence up to 54 weeks was 3.9% and 1.0%, respectively.
In a placebo-controlled factorial trial conducted for 24 weeks, the incidence of hypoglycemia during initial co-administration of this drug and metformin was 0.6% in the placebo group, 0.6% in the group administered this drug alone, 0.8% in the group administered metformin alone, and 1.6% in the group administered this drug and metformin together.
laboratory tests
The incidence of laboratory adverse reactions in the group administered 100 mg of this drug was 8.2% and in the group administered placebo, it was 9.8%. In clinical trials, a slight increase in white blood cell count (approximately 200 cells/μL difference compared to placebo administration; average baseline value of approximately 6600 cells/μL) was observed due to an increase in neutrophils. This difference has been shown in many, but not all, studies, and changes in laboratory values are not believed to be clinically relevant.
In a 12-week study, 91 patients with chronic renal impairment and 37 patients with moderate renal impairment were randomly assigned to receive 50 mg of ZELJANZ, and 14 patients with the same degree of renal impairment were randomized to placebo. The mean (standard error) increase in serum creatinine was 0.12 mg/dL (0.04) in the drug-treated group and 0.07 mg/dL (0.07) in the placebo-treated group. The clinical significance of increased serum creatinine compared to placebo is unknown.
Domestic clinical trial results
The safety and efficacy of this drug were evaluated in a bridging clinical trial conducted in 530 Asians in a multi-country, double-blind, randomized, placebo-controlled, parallel group study, of which 95 were Korean. The safety profile of this drug in Koreans was generally similar to that of placebo and showed no significant differences from the results reported in previous clinical trials.
2) Post-marketing adverse reactions
The following are additional adverse reactions identified after the marketing of this drug. Because these adverse reactions are voluntarily reported from an unspecified population, it is generally not possible to reliably predict their frequency or establish a causal relationship with drug exposure. Hypersensitivity reactions, including anaphylaxis, angioedema, rash, urticaria, cutaneous angiitis and exfoliative skin diseases including Stevens-Johnson syndrome (see section 1. Warnings), elevated liver enzymes; Acute pancreatitis, including fatal/non-fatal hemorrhagic or necrotizing pancreatitis (see sections 1. Warning, 2) Pancreatitis); Deterioration of renal function, including acute renal failure (sometimes requiring dialysis); upper respiratory tract infection; nasopharyngitis; constipation; puke; headache; Severe and disabling arthralgia (see section 5. General precautions, 2) Severe and disabling arthralgia); Bullous pemphigoid (see section 5. General precautions, 3) Bullous pemphigoid); myalgia; Pain in limbs; back pain; interstitial lung disease; pruritus; It is thrombocytopenia.
During post-marketing use, rhabdomyolysis was reported when taken with statin drugs. (Domestic clue information analysis and evaluation results)
3) Domestic post-marketing survey results
① As a result of a use result survey conducted on 3,453 people for 6 years for re-examination in Korea, the incidence of adverse events was reported to be 4.87% (168/3,453 people) [232 cases] regardless of causal relationship, and among these, the incidence of adverse drug reactions for which a causal relationship with this drug could not be ruled out was 1.56% (54/3,453 people) [64 cases]. ‘Hypoglycemia’ was reported at 0.26% (9/3,453 people) [9 cases], ‘indigestion’ and ‘dizziness’ at 0.12% (4/3,453 people) [4 cases] each, and ‘increased ALT’, ‘increased AST’, ‘diarrhea’, ‘nausea’, and ‘headache’ at 0.09% (3/3,453 people) [3 cases] each.
Serious adverse events were 0.12% (4/3,453 people) [5 cases] regardless of causal relationship, with ‘pneumonia’, ‘diabetic complications’, ‘metabolic acidosis’, ‘fall’, and ‘cardiac arrest’ occurring at 0.03% (1/3,453 people) [1 case] each. Among these, the serious adverse drug reaction was ‘diabetic complications’ at 0.03%. (1/3,453 people)[1 case] reported.
Unexpected adverse events were reported at 3.04% (105/3,453 people) [137 cases] regardless of causal relationship, ‘indigestion’ at 0.32% (11/3,453 people) [12 cases], ‘dizziness’ at 0.23% (8/3,453 people) [8 cases], ‘increased blood triglyceride’, and ‘gastritis’. 0.17% (6/3,453 people) [6 cases] were reported, and among these, unexpected adverse drug reactions for which a causal relationship with this drug cannot be ruled out were 0.93% (32/3,453 people) [35 cases], ‘indigestion’ and ‘dizziness’ at 0.12% (4/3,453 people) [4 cases] respectively, ‘increased blood triglyceride’, ‘Increased low-density lipoprotein’ and ‘hyperglycemia’ were reported in the order of 0.06% (2/3,453 people) [2 cases] each.
② As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect reporting data for this drug with the adverse event reporting data reported for all domestically approved drugs at the end of re-examination, the following are newly identified adverse events that were statistically significantly more reported for this drug compared to those reported for all other drugs. However, this result does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
· Gastrointestinal disorders: indigestion, gastritis
· Metabolic and nutritional diseases: weight loss
· Common cardiovascular diseases: high blood pressure
· Metabolic and nutritional diseases: hypernatremia
· Mental illness: erectile dysfunction
5. General precautions
1) Co-administration with drugs known to cause hypoglycemia: As is typical for co-administration with other hypoglycemic agents, hypoglycemia was observed when this drug was co-administered with insulin or sulfonylurea (see section 4. Adverse reactions). To reduce the risk of hypoglycemia caused by sulfonylureas or insulin, a reduction in sulfonylureas or insulin may be considered (see Dosage and Administration section).
2) Severe and disabling joint pain
Severe and disabling arthralgia have been reported in post-marketing studies in patients taking DPP-4 inhibitors. The onset of symptoms after drug administration varied from 1 day to several years later. Symptoms were alleviated when drug administration was stopped. In some patients, recurrence of symptoms occurred when taking the same drug or a different DPP-4 inhibitor. Consider the DPP-4 inhibitor as the cause of severe arthralgia and, if appropriate, discontinue administration.
3) Bullous pemphigoid
In post-marketing surveillance in patients taking DPP-4 inhibitors, cases of bullous pemphigus requiring hospitalization have been reported. Patients generally recovered with discontinuation of DPP-4 inhibitors and treatment with topical or systemic immunosuppressants. Patients should be advised to immediately report to their doctor if blisters or sores occur while taking this medication. If bullous pemphigus is suspected, this drug should be discontinued and the patient should be referred to a dermatologist for diagnosis and appropriate treatment.
6. Interaction
In drug interaction studies, sitagliptin did not have a clinically significant effect on the pharmacokinetics of the following drugs: metformin, rosiglitazone, glibenclamide, simvastatin, warfarin, and oral contraceptives. Based on this test, it is not expected to act on substrates of CYP3A4, CYP2C8, CYP2C9 and organic cation transporters.
Co-administration of this drug with metformin taken twice daily in patients with type 2 diabetes does not significantly change the pharmacokinetics of this drug.
Cyclosporine: When administered as a single dose in combination with 600 mg of cyclosporine, a strong p-glycoprotein inhibitor, the AUC (29%) and Cmax (68%) of sitagliptin were increased, but the change in the pharmacokinetics of sitagliptin is not expected to be clinically significant. No significant interaction is expected when coadministered with cyclosporine or other p-glycoprotein inhibitors.
Digoxin: When coadministered with 100 mg of this drug for 10 days, the plasma AUC (11%) and Cmax (18%) of digoxin were slightly increased. Appropriate monitoring must be conducted when administering digoxin, and no dosage adjustment of this drug or digoxin is necessary.
7. Administration to pregnant women, lactating women, children and the elderly
1) Administration to pregnant women
There are no controlled test results in pregnant women, so its use in pregnant women is not recommended.
2) Administration to nursing mothers
This drug is reported to be secreted into milk and plasma at a ratio of 4:1 in rats, so it is not administered to nursing mothers.
3) Administration to children
Safety and efficacy in children and adolescents under 18 years of age have not been established.
4) Administration to elderly people
Of the total subjects (3,884) in the pre-approval clinical trial, 725 were over 65 years of age and 61 were over 75 years of age. Safety and efficacy in elderly patients aged 65 years or older were similar to those in younger patients. Although there was no difference in responsiveness between this patient group and the younger patient group, it cannot be ruled out that susceptibility may be increased in some elderly patients.
This drug is known to be largely excreted by the kidneys. Elderly people are prone to decreased kidney function, so care must be taken when selecting the dose in elderly people. It is recommended that kidney function be evaluated periodically before and after administration of this drug.
8. Treatment in case of overdose
In clinical trials of this drug, single doses of up to 800 mg of this drug were administered to healthy adults. In one study administering 800 mg of this drug, an increase in mean QTc of up to 8.0 msec was observed, but this is not believed to be clinically relevant. There is no experience administering doses exceeding 800 mg in humans.
In case of overdose, general symptomatic treatment is administered (e.g., removal of unabsorbed drug from the gastrointestinal tract and clinical monitoring including electrocardiogram), and auxiliary treatment is provided depending on the patient's condition.
This drug may be partially removed by dialysis. In clinical trials, approximately 13.5% of the administered dose was removed during hemodialysis over 3 to 4 hours. Long-term hemodialysis should be considered if clinically appropriate. It is not known whether this drug is removed by peritoneal dialysis.
9. Other
1) Carcinogenicity, mutagenicity, fertility
A carcinogenicity test was conducted on male and female rats at doses of 50, 150, and 500 mg/kg/day of sitagliptin for 2 years. The incidence of combined liver adenoma/carcinoma increased in both sexes, and in females, the incidence of liver cancer increased at 500 mg/kg. This dose is almost 60 times the maximum recommended human dose (MRHD) of 100 mg/day based on AUC comparison. Liver tumors were not observed at 150 mg/kg, which is nearly 20 times the maximum recommended human dose.
A carcinogenicity test was conducted on male and female mice at doses of 50, 125, 250, and 500 mg/kg/day of sitagliptin for 2 years. At 500 mg/kg, which is almost 70 times the maximum recommended human dose, there was no increase in tumor occurrence in any organ. Sitagliptin was not shown to be mutagenic or cause chromosomal abnormalities in a series of genotoxicity studies, such as reverse mutation (Ames) test using bacteria, in vitro chromosomal aberration test and in vitro cytogenetic analysis using CHO cells, in vitro alkaline elution assay in rat liver cells, and in vivo micronucleus test using mouse hematopoietic cells.
In a rat fertility test, doses of 125, 250, and 1000 mg/kg were administered to males for 4 weeks before mating, at the time of mating, and until the end of mating (about 8 weeks in total), and to females, it was orally administered from 2 weeks before mating until the 7th day of pregnancy. No fertility abnormalities were observed at 125 mg/kg (approximately 12 times the maximum recommended human dose). At high doses (25 and 100 times the maximum recommended human dose), a dose-independent increase in resorption was observed in females.
2) Reproductive toxicity
In reproductive toxicity tests conducted in rats and rabbits, there was no damage to fertility or fetuses when sitagliptin was administered at doses up to 125 mg/kg (corresponding to exposure 12 times the maximum recommended human dose). However, there are no controlled test results for pregnant women, and the results of reproductive toxicity tests in animals do not always predict reactions in humans, so use in pregnant women is not recommended.
When sitagliptin was administered to pregnant female rats and rabbits on days 6 to 20 of pregnancy (organ formation period), there were no teratogenic effects when administered at doses up to 250 mg/kg in rats and up to 125 mg/kg in rabbits, or approximately 30 or 20 times the maximum recommended human dose of 100 mg/day based on AUC comparison. When administered orally in rats at 1000 mg/kg/day (equivalent to approximately 100 times the exposure of 100 mg/day, the maximum recommended dose in humans), the incidence of rib hypoplasia in offspring increased with higher doses.
Body weight decreased in both male and female rat pups administered orally at a dose of 1000 mg/kg/day from the 6th day of pregnancy to the 21st day of lactation. No abnormalities in function or behavior were observed.
About 45% of sitagliptin passed through the placenta at 2 hours and 80% at 24 hours after administration to pregnant rats. In rabbits, the rate was approximately 66% at 2 hours and 30% at 24 hours after administration.
3) TECOS cardiovascular safety clinical trial
The primary cardiovascular endpoint is a composite outcome of cardiovascular-related death, non-fatal myocardial infarction, non-fatal stroke, or first event of unstable angina requiring hospitalization. Secondary cardiovascular endpoints were first event of cardiovascular-related death, non-fatal myocardial infarction, or non-fatal stroke; first event of the individual components of the first-order composite variable; death from all causes; Hospitalizations due to congestive heart failure were included.
After a median follow-up period of 3 years, sitagliptin added to usual care did not increase the risk of major adverse cardiovascular events or hospitalization for heart failure (Table 4).
Table 4. Rates of composite cardiovascular outcomes and key secondary outcomes.
* Table: refer to manual
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/box (10 tablets/PTPX3)
7. Period of use
36 months from date of manufacture
- Active ingredient: Sitagliptin phosphate (in-house specification) · · · · · · · 62.04mg (50mg as sitagliptin)
- Additives: Anhydrous calcium hydrogen phosphate, microcrystalline cellulose, magnesium stearate, Opadry II light beige (85F17498), croscarmellose sodium, sodium stearyl fumarate
2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve blood sugar control in patients with type 2 diabetes.
1. This drug is administered as monotherapy.
2. If there is no previous experience of diabetes medication and it is difficult to control blood sugar levels sufficiently with monotherapy, administer in combination with metformin.
3. If sufficient blood sugar control cannot be achieved with sulfonylurea, metformin, thiazolidinedione, or insulin alone, administer this drug together.
4. If sufficient blood sugar control cannot be achieved with combination therapy of sulfonylurea and metformin, or combination therapy of thiazolidinedione and metformin, or combination therapy of insulin and metformin, this drug should be administered together.
3. Dosage and dosage
This drug is administered at a dose of 100 mg once a day when used as monotherapy or combination therapy, and the maximum daily dose is 100 mg. This medicine can be taken without regard to meals.
When coadministered with sulfonylurea or insulin, reduction of sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea or insulin-induced hypoglycemia.
(Refer to Precautions for Use, Section 5. General Precautions).
Patients with renal impairment
Since dose adjustment is necessary depending on renal function, it is recommended to evaluate renal function periodically before and after administration of this drug.
1. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2).
2. No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2).
3. In patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once a day.
4. Patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis.
(Glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once a day. This drug can be administered regardless of the timing of dialysis.
4. Precautions for use
1. Warning
1) Hypersensitivity reaction
Severe hypersensitivity reactions have been reported in patients receiving this drug post-marketing, including anaphylaxis, angioedema, and exfoliative skin disorders, including Stevens-Johnson syndrome. Because they are voluntarily reported from an unspecified population, it is generally not possible to reliably estimate their incidence or establish a causal relationship with drug exposure. The onset of this reaction occurred within the first 3 months of drug treatment and has also been reported after the first dose. If hypersensitivity reaction is suspected, discontinue this drug, evaluate other potential reasons for the occurrence, and implement other diabetes treatment (see 2. Do not administer to the following patients and 4. Adverse reactions, 2) Post-marketing adverse reactions).
2) Pancreatitis
Acute pancreatitis, including fatal/non-fatal hemorrhagic or necrotizing pancreatitis, has been reported in patients receiving sitagliptin (see Section 4. Adverse Reactions). After starting treatment with this drug, carefully observe whether symptoms of pancreatitis appear. If pancreatitis is suspected, administration of this drug and other suspected drugs should be discontinued.
2. Do not administer to the following patients
1) Patients with type 1 diabetes or diabetic ketoacidosis
2) Patients with known hypersensitivity such as anaphylaxis or angioedema to this drug or its components (see 1. Warning section)
3. Administer with caution to the following patients:
1) Patients with renal impairment: This drug is excreted through the kidneys. To achieve blood levels similar to those in patients with normal renal function, lower doses are recommended in patients with a glomerular filtration rate [eGFR] <45 mL/min/1.73 m2? and in patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (see Dosage and Administration, Patients with Renal Impairment).
4. Adverse reactions
1) Clinical trials
Because clinical trials are conducted under a wide range of diverse conditions, the incidence of adverse reactions observed in clinical trials cannot be directly compared to the rates in clinical trials of other drugs, and cannot reflect the rates observed under actual use environments.
In clinical trials of this drug, when this drug was administered as monotherapy or combination therapy (metformin or pioglitazone or rosiglitazone and metformin), the incidence of adverse reactions and hypoglycemia was generally similar to that reported for placebo. Cases where treatment was discontinued due to adverse reactions were similar to those in the placebo group.
During glimepiride or glimepiride and metformin combination therapy, the frequency of adverse reactions in the drug-treated group was higher than the placebo group (Table 3). This is partly due to the high incidence of hypoglycemia in the group receiving this drug. Discontinuation of treatment due to adverse reactions was similar to that in the placebo group.
Two placebo-controlled monotherapy studies conducted for 18 and 24 weeks included groups receiving 100 mg and 200 mg of this drug daily and placebo. Five additional placebo-controlled combination studies administered metformin, pioglitazone, rosiglitazone, and stable doses of metformin, glimepiride (±metformin), or insulin (±metformin), respectively, plus 100 mg of this drug or placebo daily.
In these clinical trials, adverse reactions reported at a frequency of 5% or more and more frequently than placebo among patients taking 100 mg of this drug daily for 18 weeks, regardless of causality assessment, excluding hypoglycemia, are listed in Table 1. The incidence of hypoglycemia is shown in Table 3.
Table 1. Placebo-controlled clinical trials with this drug as monotherapy or in combination (pioglitazone, or rosiglitazone and metformin, or glimepiride (±metformin)): Adverse reactions, excluding hypoglycemia, reported at a frequency of 5% or more and more frequently than placebo, regardless of causality assessment†
* Table: refer to manual
† ITT (Intent-to-treat) subject group
In patients who received additional co-administration of this drug and metformin for 24 weeks, there were no adverse reactions reported at a frequency of more than 5% and more frequently than placebo, regardless of causality assessment.
In patients who received this drug in combination with a stable dose of insulin (±metformin) for 24 weeks, there were no adverse reactions except hypoglycemia, which was reported at a frequency of more than 5% and more frequently than placebo, regardless of causality assessment (see Table 3 for hypoglycemia). In patients receiving additional co-administration of this drug during another 24-week insulin intensification period (±metformin), the adverse reaction reported at a frequency greater than 5% and more frequently than placebo, regardless of causality assessment, was diarrhea (5.2% of this drug; 3.3% of placebo).
In patients receiving this drug in combination with rosiglitazone and metformin for 54 weeks, adverse reactions reported at a frequency of 5% or more and more frequently than placebo, regardless of causality assessment, were: upper respiratory tract infection (15.5% of this drug, 6.2% of placebo), nasopharyngitis (11.0%, 9.3%), peripheral edema (8.3%, 5.2%), and headache (5.5%). It was 4.1%).
As a result of a comprehensive analysis of two monotherapy clinical trials, a clinical trial with additional combination therapy with metformin, and a clinical trial with additional combination therapy with pioglitazone, the occurrence of specific gastrointestinal adverse reactions in patients treated with this drug was as follows: abdominal pain (2.3% with this drug 100 mg, 2.1% with placebo), nausea (1.4% with this drug 100 mg, 0.6% with placebo), and diarrhea (100 mg with this drug). 3.0%, placebo 2.3%)
In a 24-week placebo-controlled factorial trial, adverse reactions that were reported at a frequency of 5% or more or more frequently than placebo, regardless of the causality assessment, during initial co-administration of this drug and metformin are listed in Table 2.
Table 2. Initial combination therapy with this drug and metformin: Adverse reactions reported at a frequency of 5% or more and more frequently than those administered with this drug alone, metformin alone, and placebo, regardless of causality assessment†
* Table: refer to manual
† ITT (Intent to treat) subject group
‡ Integrated data of patients receiving low and high doses of metformin
No clinically significant changes in vital signs or ECG (including QTc interval) were observed with administration of this drug.
pancreatitis
When the results of 19 double-blind clinical trials of 10,246 patients randomly assigned to sitagliptin 100 mg/day (N=5429) or the corresponding control group (active comparator or placebo) (N=4817) were pooled and analyzed, the incidence of acute pancreatitis in each group was 0.1 per 100 patient-years (in the sitagliptin group) reported in 4 patients out of 4708 patient-years and in the control group in 4 patients out of 3942 patient-years). In the TECOS cardiovascular safety trial, the incidence of acute pancreatitis was reported to be 0.11 (23/7,332, 25 cases) per 100 patient-years in the sitagliptin group and 0.06 (12/7,339, 17 cases) per 100 patient-years in the placebo group. (See 1. Warning, 2) Pancreatitis section, TECOS cardiovascular safety clinical trial section)
TECOS Cardiovascular Safety Trial (TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin)
The intent-to-treat arm of the cardiovascular safety clinical trial of this drug included 7,332 patients who received 100 mg of this drug daily (or 50 mg daily if eGFR ≥ 30 and <50 mL/min/1.73 m2 at baseline) and 7,339 patients who received placebo. In this clinical trial, this drug or placebo was administered in addition to usual treatment in each country related to glycated hemoglobin (HbA1c) and cardiovascular (CV) risk factors. Administration of this drug did not increase the risk of hospitalization due to major cardiovascular disease or heart failure (see Section 9. Other). The reported incidence of serious adverse reactions was similar at 12.7% in the drug-treated group and 12.4% in the placebo-treated group.
Severe hypoglycemia was reported in 2.2% of the this medicine group (160 patients; 0.78 per 100 patient-years) and 1.9% of the placebo group (143 patients; 0.70 per 100 patient-years). Among patients receiving insulin and/or a sulfonylurea, the incidence was 2.7% with this medicine (138/5,021 patients) and 2.5% with placebo (125/4,931 patients). Among patients not receiving insulin or a sulfonylurea, the incidence was 1.0% with this medicine (22/2,311 patients) and 0.7% with placebo (18/2,408 patients). Confirmed acute pancreatitis occurred in 0.3% of the this medicine group and 0.2% of the placebo group.
low blood sugar
In all studies (9), hypoglycemic adverse events were based on reports of symptomatic hypoglycemia. Although blood sugar measurement was not necessarily involved, most reports of hypoglycemia (74%) were below 70 mg/dL when measured. The proportion of patients with one or more hypoglycemic adverse events when this drug was administered in combination with a sulfonylurea or insulin was higher than in the placebo group (see Table 3).
Table 3. Placebo-controlled clinical trials administering this drug in combination with glimepiride (±metformin) or insulin (±metformin): Incidence of reported hypoglycemia, regardless of causality assessment†
* Table: refer to manual
† Hypoglycemic adverse events were based on reports of symptomatic hypoglycemia and were not necessarily accompanied by blood glucose measurements; ITT (Intent to treat) group
‡ Based on total number of incidents (a person may report multiple incidents)
§ Severe hypoglycemia was defined as requiring medical attention, reaching a reduced level of consciousness, losing consciousness, or having a seizure.
As a result of a comprehensive analysis of two monotherapy clinical trials, a clinical trial with additional combination therapy with metformin, and a clinical trial with additional combination therapy with pioglitazone, the incidence of hypoglycemia as an adverse reaction in patients administered 100 mg of this drug was similar to that of placebo (1.2% for 100 mg of this drug, 0.9% for placebo).
In a clinical trial combining this drug with rosiglitazone and metformin, the incidence of hypoglycemia up to 18 weeks was 2.2% in the drug-treated group and 0.0% in the placebo-treated group. The incidence up to 54 weeks was 3.9% and 1.0%, respectively.
In a placebo-controlled factorial trial conducted for 24 weeks, the incidence of hypoglycemia during initial co-administration of this drug and metformin was 0.6% in the placebo group, 0.6% in the group administered this drug alone, 0.8% in the group administered metformin alone, and 1.6% in the group administered this drug and metformin together.
laboratory tests
The incidence of laboratory adverse reactions in the group administered 100 mg of this drug was 8.2% and in the group administered placebo, it was 9.8%. In clinical trials, a slight increase in white blood cell count (approximately 200 cells/μL difference compared to placebo administration; average baseline value of approximately 6600 cells/μL) was observed due to an increase in neutrophils. This difference has been shown in many, but not all, studies, and changes in laboratory values are not believed to be clinically relevant.
In a 12-week study, 91 patients with chronic renal impairment and 37 patients with moderate renal impairment were randomly assigned to receive 50 mg of ZELJANZ, and 14 patients with the same degree of renal impairment were randomized to placebo. The mean (standard error) increase in serum creatinine was 0.12 mg/dL (0.04) in the drug-treated group and 0.07 mg/dL (0.07) in the placebo-treated group. The clinical significance of increased serum creatinine compared to placebo is unknown.
Domestic clinical trial results
The safety and efficacy of this drug were evaluated in a bridging clinical trial conducted in 530 Asians in a multi-country, double-blind, randomized, placebo-controlled, parallel group study, of which 95 were Korean. The safety profile of this drug in Koreans was generally similar to that of placebo and showed no significant differences from the results reported in previous clinical trials.
2) Post-marketing adverse reactions
The following are additional adverse reactions identified after the marketing of this drug. Because these adverse reactions are voluntarily reported from an unspecified population, it is generally not possible to reliably predict their frequency or establish a causal relationship with drug exposure. Hypersensitivity reactions, including anaphylaxis, angioedema, rash, urticaria, cutaneous angiitis and exfoliative skin diseases including Stevens-Johnson syndrome (see section 1. Warnings), elevated liver enzymes; Acute pancreatitis, including fatal/non-fatal hemorrhagic or necrotizing pancreatitis (see sections 1. Warning, 2) Pancreatitis); Deterioration of renal function, including acute renal failure (sometimes requiring dialysis); upper respiratory tract infection; nasopharyngitis; constipation; puke; headache; Severe and disabling arthralgia (see section 5. General precautions, 2) Severe and disabling arthralgia); Bullous pemphigoid (see section 5. General precautions, 3) Bullous pemphigoid); myalgia; Pain in limbs; back pain; interstitial lung disease; pruritus; It is thrombocytopenia.
During post-marketing use, rhabdomyolysis was reported when taken with statin drugs. (Domestic clue information analysis and evaluation results)
3) Domestic post-marketing survey results
① As a result of a use result survey conducted on 3,453 people for 6 years for re-examination in Korea, the incidence of adverse events was reported to be 4.87% (168/3,453 people) [232 cases] regardless of causal relationship, and among these, the incidence of adverse drug reactions for which a causal relationship with this drug could not be ruled out was 1.56% (54/3,453 people) [64 cases]. ‘Hypoglycemia’ was reported at 0.26% (9/3,453 people) [9 cases], ‘indigestion’ and ‘dizziness’ at 0.12% (4/3,453 people) [4 cases] each, and ‘increased ALT’, ‘increased AST’, ‘diarrhea’, ‘nausea’, and ‘headache’ at 0.09% (3/3,453 people) [3 cases] each.
Serious adverse events were 0.12% (4/3,453 people) [5 cases] regardless of causal relationship, with ‘pneumonia’, ‘diabetic complications’, ‘metabolic acidosis’, ‘fall’, and ‘cardiac arrest’ occurring at 0.03% (1/3,453 people) [1 case] each. Among these, the serious adverse drug reaction was ‘diabetic complications’ at 0.03%. (1/3,453 people)[1 case] reported.
Unexpected adverse events were reported at 3.04% (105/3,453 people) [137 cases] regardless of causal relationship, ‘indigestion’ at 0.32% (11/3,453 people) [12 cases], ‘dizziness’ at 0.23% (8/3,453 people) [8 cases], ‘increased blood triglyceride’, and ‘gastritis’. 0.17% (6/3,453 people) [6 cases] were reported, and among these, unexpected adverse drug reactions for which a causal relationship with this drug cannot be ruled out were 0.93% (32/3,453 people) [35 cases], ‘indigestion’ and ‘dizziness’ at 0.12% (4/3,453 people) [4 cases] respectively, ‘increased blood triglyceride’, ‘Increased low-density lipoprotein’ and ‘hyperglycemia’ were reported in the order of 0.06% (2/3,453 people) [2 cases] each.
② As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect reporting data for this drug with the adverse event reporting data reported for all domestically approved drugs at the end of re-examination, the following are newly identified adverse events that were statistically significantly more reported for this drug compared to those reported for all other drugs. However, this result does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
· Gastrointestinal disorders: indigestion, gastritis
· Metabolic and nutritional diseases: weight loss
· Common cardiovascular diseases: high blood pressure
· Metabolic and nutritional diseases: hypernatremia
· Mental illness: erectile dysfunction
5. General precautions
1) Co-administration with drugs known to cause hypoglycemia: As is typical for co-administration with other hypoglycemic agents, hypoglycemia was observed when this drug was co-administered with insulin or sulfonylurea (see section 4. Adverse reactions). To reduce the risk of hypoglycemia caused by sulfonylureas or insulin, a reduction in sulfonylureas or insulin may be considered (see Dosage and Administration section).
2) Severe and disabling joint pain
Severe and disabling arthralgia have been reported in post-marketing studies in patients taking DPP-4 inhibitors. The onset of symptoms after drug administration varied from 1 day to several years later. Symptoms were alleviated when drug administration was stopped. In some patients, recurrence of symptoms occurred when taking the same drug or a different DPP-4 inhibitor. Consider the DPP-4 inhibitor as the cause of severe arthralgia and, if appropriate, discontinue administration.
3) Bullous pemphigoid
In post-marketing surveillance in patients taking DPP-4 inhibitors, cases of bullous pemphigus requiring hospitalization have been reported. Patients generally recovered with discontinuation of DPP-4 inhibitors and treatment with topical or systemic immunosuppressants. Patients should be advised to immediately report to their doctor if blisters or sores occur while taking this medication. If bullous pemphigus is suspected, this drug should be discontinued and the patient should be referred to a dermatologist for diagnosis and appropriate treatment.
6. Interaction
In drug interaction studies, sitagliptin did not have a clinically significant effect on the pharmacokinetics of the following drugs: metformin, rosiglitazone, glibenclamide, simvastatin, warfarin, and oral contraceptives. Based on this test, it is not expected to act on substrates of CYP3A4, CYP2C8, CYP2C9 and organic cation transporters.
Co-administration of this drug with metformin taken twice daily in patients with type 2 diabetes does not significantly change the pharmacokinetics of this drug.
Cyclosporine: When administered as a single dose in combination with 600 mg of cyclosporine, a strong p-glycoprotein inhibitor, the AUC (29%) and Cmax (68%) of sitagliptin were increased, but the change in the pharmacokinetics of sitagliptin is not expected to be clinically significant. No significant interaction is expected when coadministered with cyclosporine or other p-glycoprotein inhibitors.
Digoxin: When coadministered with 100 mg of this drug for 10 days, the plasma AUC (11%) and Cmax (18%) of digoxin were slightly increased. Appropriate monitoring must be conducted when administering digoxin, and no dosage adjustment of this drug or digoxin is necessary.
7. Administration to pregnant women, lactating women, children and the elderly
1) Administration to pregnant women
There are no controlled test results in pregnant women, so its use in pregnant women is not recommended.
2) Administration to nursing mothers
This drug is reported to be secreted into milk and plasma at a ratio of 4:1 in rats, so it is not administered to nursing mothers.
3) Administration to children
Safety and efficacy in children and adolescents under 18 years of age have not been established.
4) Administration to elderly people
Of the total subjects (3,884) in the pre-approval clinical trial, 725 were over 65 years of age and 61 were over 75 years of age. Safety and efficacy in elderly patients aged 65 years or older were similar to those in younger patients. Although there was no difference in responsiveness between this patient group and the younger patient group, it cannot be ruled out that susceptibility may be increased in some elderly patients.
This drug is known to be largely excreted by the kidneys. Elderly people are prone to decreased kidney function, so care must be taken when selecting the dose in elderly people. It is recommended that kidney function be evaluated periodically before and after administration of this drug.
8. Treatment in case of overdose
In clinical trials of this drug, single doses of up to 800 mg of this drug were administered to healthy adults. In one study administering 800 mg of this drug, an increase in mean QTc of up to 8.0 msec was observed, but this is not believed to be clinically relevant. There is no experience administering doses exceeding 800 mg in humans.
In case of overdose, general symptomatic treatment is administered (e.g., removal of unabsorbed drug from the gastrointestinal tract and clinical monitoring including electrocardiogram), and auxiliary treatment is provided depending on the patient's condition.
This drug may be partially removed by dialysis. In clinical trials, approximately 13.5% of the administered dose was removed during hemodialysis over 3 to 4 hours. Long-term hemodialysis should be considered if clinically appropriate. It is not known whether this drug is removed by peritoneal dialysis.
9. Other
1) Carcinogenicity, mutagenicity, fertility
A carcinogenicity test was conducted on male and female rats at doses of 50, 150, and 500 mg/kg/day of sitagliptin for 2 years. The incidence of combined liver adenoma/carcinoma increased in both sexes, and in females, the incidence of liver cancer increased at 500 mg/kg. This dose is almost 60 times the maximum recommended human dose (MRHD) of 100 mg/day based on AUC comparison. Liver tumors were not observed at 150 mg/kg, which is nearly 20 times the maximum recommended human dose.
A carcinogenicity test was conducted on male and female mice at doses of 50, 125, 250, and 500 mg/kg/day of sitagliptin for 2 years. At 500 mg/kg, which is almost 70 times the maximum recommended human dose, there was no increase in tumor occurrence in any organ. Sitagliptin was not shown to be mutagenic or cause chromosomal abnormalities in a series of genotoxicity studies, such as reverse mutation (Ames) test using bacteria, in vitro chromosomal aberration test and in vitro cytogenetic analysis using CHO cells, in vitro alkaline elution assay in rat liver cells, and in vivo micronucleus test using mouse hematopoietic cells.
In a rat fertility test, doses of 125, 250, and 1000 mg/kg were administered to males for 4 weeks before mating, at the time of mating, and until the end of mating (about 8 weeks in total), and to females, it was orally administered from 2 weeks before mating until the 7th day of pregnancy. No fertility abnormalities were observed at 125 mg/kg (approximately 12 times the maximum recommended human dose). At high doses (25 and 100 times the maximum recommended human dose), a dose-independent increase in resorption was observed in females.
2) Reproductive toxicity
In reproductive toxicity tests conducted in rats and rabbits, there was no damage to fertility or fetuses when sitagliptin was administered at doses up to 125 mg/kg (corresponding to exposure 12 times the maximum recommended human dose). However, there are no controlled test results for pregnant women, and the results of reproductive toxicity tests in animals do not always predict reactions in humans, so use in pregnant women is not recommended.
When sitagliptin was administered to pregnant female rats and rabbits on days 6 to 20 of pregnancy (organ formation period), there were no teratogenic effects when administered at doses up to 250 mg/kg in rats and up to 125 mg/kg in rabbits, or approximately 30 or 20 times the maximum recommended human dose of 100 mg/day based on AUC comparison. When administered orally in rats at 1000 mg/kg/day (equivalent to approximately 100 times the exposure of 100 mg/day, the maximum recommended dose in humans), the incidence of rib hypoplasia in offspring increased with higher doses.
Body weight decreased in both male and female rat pups administered orally at a dose of 1000 mg/kg/day from the 6th day of pregnancy to the 21st day of lactation. No abnormalities in function or behavior were observed.
About 45% of sitagliptin passed through the placenta at 2 hours and 80% at 24 hours after administration to pregnant rats. In rabbits, the rate was approximately 66% at 2 hours and 30% at 24 hours after administration.
3) TECOS cardiovascular safety clinical trial
The primary cardiovascular endpoint is a composite outcome of cardiovascular-related death, non-fatal myocardial infarction, non-fatal stroke, or first event of unstable angina requiring hospitalization. Secondary cardiovascular endpoints were first event of cardiovascular-related death, non-fatal myocardial infarction, or non-fatal stroke; first event of the individual components of the first-order composite variable; death from all causes; Hospitalizations due to congestive heart failure were included.
After a median follow-up period of 3 years, sitagliptin added to usual care did not increase the risk of major adverse cardiovascular events or hospitalization for heart failure (Table 4).
Table 4. Rates of composite cardiovascular outcomes and key secondary outcomes.
* Table: refer to manual
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/box (10 tablets/PTPX3)
7. Period of use
36 months from date of manufacture